Cancer and CBD: "The Antitumor Activity of Plant-derived Non-psychoactive Cannabinoids"
During the last decade, several studies have now shown that CB1 and CB2 receptor agonists can act as direct antitumor agents in a variety of aggressive cancers: the ability of non-psychoactive cannabinoids to induce autophagy and apoptotic-mediated cancer cell death,
and enhance the activity of first-line agents commonly used in cancer treatment.
For example, the second most abundant cannabinoid in CS is the non-psychoactive cannabidiol (CBD). Using animal models, CBD has been shown to inhibit the progression of many types of cancer including glioblastoma (GBM), breast, lung, prostate and colon cancer. source:
Read that again. Yes, a plant that can be grown and consumed can have "shown to inhibit the progression of many types of cancer."
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
So ask yourself, if it can function as a treatment after diagnosis - what type of protections could CBD offer before one is ill or stricken with cancer, epilepsy, or arthritis?
Please read, share and let's change the way we treat ourselves as a nation and as individuals.
Keywords: cannabinoid, cannabidiol, cancer, reactive oxygen species
This review will center on mechanisms by which CBD, and other plant-derived cannabinoids inefficient at activating cannabinoid receptors, inhibit tumor cell viability, invasion, metastasis, angiogenesis, and the stem-like potential of cancer stem cells.